LIST OF PUBLICATIONS

Rabea Asleh MD PhD MHA FACC

(January 2021)

DOCTORAL DISSERTATION

THESIS

PhD Thesis: "Elucidation of the Mechanisms Responsible for the Interaction Between the Haptoglobin Polymorphism and Diabetic Cardiovascular Disease" Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel (2006); Supervisor: Professor Andrew P. Levy. Publications# 1-10.

BOOKS

BOOKS EDITED

CHAPTERS IN COLLECTIONS

1. **Chapter: Genetics of Heart Failure**. Encyclopedia of Cardiovascular Research and Medicine. 2018, Pages 368-379. https://www.sciencedirect.com/science/article/pii/B9780128096574109007
2. **Chapter: Short and Long Term Mechanical Circulatory Support in Heart Failure**. Mechanical Circulatory Support: Principles and Applications, 2nd Edition. Oxford University Press; January 3, 2020.

ARTICLES

REFEREED PAPERS IN PROFESSIONAL JOURNALS

BASIC AND CLINICAL RESEARCH

Abbreviations: PI= principal investigator, C= coinvestigator, S= student, T= technician.

1. **Asleh R** (PI), Marsh S (C), Shiltruck M (C), Binah O (C), Guetta J (C), Lejbkowicz F (C), Enav B (C), Shehadeh N (C), Kanter Y (C), Lache O (C), Cohen O (C), Levy NS (C), Levy AP (PI). Genetically Determined Heterogeneity in Hemoglobin Scavenging and

Susceptibility to Diabetic Cardiovascular Disease. Circulation Res. 2003; 92: 1193-1200. Impact factor: 15.9; Rank: 2/65 (Peripheral Vascular Disease), 5/136 (Cardiac and Cardiovascular Systems); Citations: 213.

2. Shilkrut M, Yaniv G (C), **Asleh R** (C), Levy AP (C), Larish S (C), Binah O (PI). Tyrosine Kinase Inhibitors Block Fas Mediated Deleterious Effects in Normoxic and Hypoxic Ventricular Myocytes. J Mol Cell Cardiol. 2003;10:1229-1240. Impact factor: 5.1; 29/136 (Cardiac and Cardiovascular Systems); 15.
3. **Asleh R** (PI), Suleiman M (PI), Cabantchik Z (C), Breuer W (C), Aronson D (C), Suleiman A (C), Miller-Lotan R (C), Hammerman H (C), Levy AP (PI). Serum Chelatable Redox-Active Iron Is an Independent Predictor of Mortality After Myocardial Infarction in Individuals With Diabetes Mellitus. Diabetes Care. 2004,27: 2730-2732. Impact factor: 15.3; 4/145 (Endocrinology and Metabolism); 30.
4. **Asleh R** (PI), Guetta J (C), Kalet-Litman S (C), Miller-Lotan R (C), Levy AP (PI). Haptoglobin Genotype and Diabetes Dependent Differences in Iron Mediated Oxidative Stress In Vitro and In Vivo. Circulation Res. 2005; 96: 435-441. Impact factor: 15.9; 2/65 (Peripheral Vascular Disease), 5/136 (Cardiac and Cardiovascular Systems); 175.
5. Suleiman M (PI), Aronson D (C), **Asleh R** (C), Kapelovich MR (C), Roguin A (C), Meisel SR (C), Shochat M (C), Suleiman A (C), Reisner SA (C), Markiewicz W (C), Hammerman H (C), Lotan R (C), Levy NS (C), Levy AP (PI). Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients With Diabetes and Acute Myocardial Infarction. Diabetes. 2005; 54: 2802-2806. Impact factor: 7.2; 11/145 (Endocrinology and Metabolism); 116.
6. **Asleh R** (PI), Miller-Lotan R (C), Aviram M (C), Hayek T (C), Yulish M (C), Levy JE (C), Miller B (C), Blum S (C), Milman U (C), Shapira C (C), Levy AP (PI). Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo. Circulation Res. 2006; 99: 1419-1425. Impact factor: 15.9; 2/65 (Peripheral Vascular Disease), 5/136 (Cardiac and Cardiovascular Systems); 60.
7. Blum S (PI), Asaf R (C), Guetta J (C), Miller-Lotan R (C), **Asleh R** (C), Kremer R (C), Levy NS (C), Berger FG (C), Fu X (C), Zhang R (C), Hazen SL (C), Levy AP (PI). Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice. J Am Coll Cardiol. 2007; 49:82-87. Impact factor: 18.6; 3/136 (Cardiac and Cardiovascular Systems); 37.
8. Levy AP (PI), Purosothaman KR (C), Levy NS (C), Purosothaman M (C), Strauss M (C), **Asleh R** (C), Marsh S (C), Cohen O (C), Moestrup SK (C), Moller HJ (C), Zias EA (C), Benhayon D (C), Fuster V (C), Moreno PR (PI). Downregulation of the Hemoglobin Scavenger Receptor in Individuals With Diabetes and the Haptoglobin 2-2 Genotype: Implications for the Response to Intraplaque Hemorrhage and Plaque Vulnerability.

Circulation Res. 2007; 101:106-110. Impact factor: 15.9; 2/65 (Peripheral Vascular Disease), 5/136 (Cardiac and Cardiovascular Systems); 104.

9. **Asleh R** (PI), Blum S (C), Kalet-Litman S (C), Alsheik J (C),Miller-Lotan R (C), Asaf R (C), Rock W (C), Aviram M (C), Milman U (C), Shapira C (C),Abassi Z (C), Levy AP (PI). Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype. Diabetes. 2008; 57: 2794-2800. Impact factor: 7.2; 11/145 (Endocrinology and Metabolism); 95.
10. Schwartz A (PI), Blum S (C), **Asleh R** (C), Pollak M (C), Levy AP (PI). Pharmacogenomic Application of the Haptoglobin Genotype in the Treatment of HDL Dysfunction. Pharmgenomics Pers Med. 2009; 2:1-8. Impact factor: 2.7; 123/267 (Pharmacology and Pharmacy); 3.
11. Nakhoul FM (PI), Miller-Lotan R (C), Awad H (C), **Asleh R** (C), Jad K (C), Nakhoul N (S), Asaf R (S), Abu-Seleh N (S), Levy AP (PI). Pharmacogenomic Effect of Vitamin E on Kidney Structure and Function in Transgenic Mice With the Haptoglobin 2-2 Genotype and Diabetes Mellitus. Am J Phys Renal Physiol. 2009; 296: F830-838. Impact factor: 3.3; 16/80 (Urology and Nephrology), 24/81 (Physiology); 26.
12. **Asleh R** (PI), Levy AP (PI). Divergent Effects of α-Tocopherol and Vitamin C on the Generation of Dysfunctional HDL Associated With Diabetes and the Haptoglobin 2-2 Genotype. Antioxidant Redox Signaling. 2010; 12:209-217. Impact factor: 5.8; 41/299 (Biochemistry and Molecular Biology), 19/145 (Endocrinology and Metabolism); 27.
13. Blum S (PI), Vardi M (C), Brown JB (C), Russell A (C), Milman U (C), Shapira C (C), Levy NS (C), Miller-Lotan R (C), **Asleh R** (C), Levy AP (PI). Vitamin E Reduces Cardiovascular Disease in Individuals With Diabetes Mellitus and the Haptoglobin 2-2 Genotype. Pharmacogenomics. 2010; 11:675-684. Impact factor: 2.3; 161/267 (Pharmacology and Pharmacy); 84.
14. Farbstein D (PI), Blum S (C), Pollak M (C), Asaf R (C), Viener HL (C), Lache O (C), **Asleh R** (C), Miller-Lotan R (C), Barkay I (C), Star M (C), Schwartz A (C), Kalet-Littman S (C), Ozeri D (C), Vaya J (C), Tavori H (C), Vardi M (C), Laor A (C), Bucher SE (C), Anbinder Y (C), Moskovich D (C), Abbas N (C), Perry N (C), Levy Y (C), Levy AP (PI). Vitamin E Therapy Results in a Reduction in HDL Function in Individuals With Diabetes and the Haptoglobin 2-1 Genotype. Atherosclerosis. 2011; 219: 240-4. Impact factor: 4.3; 12/65 (Peripheral Vascular Disease), 37/136 (Cardiac and Cardiovascular Systems); 33.
15. **Asleh R** (PI), Nakhoul FM (C), Miller-Lotan R (C), Awad H (C), Farbstein D (C), Levy NS (C), Ianco T (C), Manov I (C), Laue M (C), Traber M (C), Leopold K (C), Levy AP (PI). Poor Lysosomal Membrane Integrity in Proximal Tubule Cells of Haptoglobin 2-2 Genotype Mice With Diabetes Mellitus. Free Radic Biol Med. 2012; 53: 779-86. Impact factor: 5.7; 43/299 (Biochemistry and Molecular Biology), 21/145 (Endocrinology and Metabolism); 14.

16. **Asleh R** (PI), Ward J (S), Levy NS (C), Safuri S (S), Aronson D (C), Levy AP (C). Haptoglobin Genotype-Dependent Differences in Macrophage Lysosomal Injury. J. Biol Chem. 2014; 289:16313-16325. Impact factor: 4.1; 81/299 (Biochemistry and Molecular Biology); 11.
17. Veiner HL (PI), Gorbatov R (C), Vardi M, Doros G (C), Zohar Y,Sabo E (C), **Asleh R** (C)**,** Levy NS (C), Goldfarb LJ (C), Berk TA (C), Haas T (C), Shalom H (T), Suss-Toby E (C), Kam A,Kaplan M (C), Tamir R (C), Ziskind A (C), Levy AP (PI). Pharmacogenomic Interaction Between the Haptoglobin Genotype and Vitamin E on Atherosclerotic Plaque Progression and Stability. Atherosclerosis. 2015; 239:232-239. Impact factor: 4.3; 12/65 (Peripheral Vascular Disease), 37/136 (Cardiac and Cardiovascular Systems); 8.
18. Costacou T (PI), Levy AP (C), Miller RG (C), Snell-Bergeon J (C), **Asleh R** (C), Farbstein D (C), Fickley CE (C), Pambianco G (C), de la Vega R (C), Evans RW (C), Orchard TJ (C). Effect of Vitamin E Supplementation on HDL Function by Haptoglobin Genotype in Type 1 Diabetes: Results From the HapE Randomized Crossover Pilot Trial. Acta Diabetol. 2016; 53: 243-50. Impact factor: 3.0; 78/145 (Endocrinology and Metabolism); 16.
19. **Asleh R** (PI), Levy NS (C), Doros G (C), Costacou T (C), Robinson JG (C), Blum S (C), Goldenstein H (C), Boden WE (C), Simmons DL (C), Lacy MA (C), Grunberger G (C), Anderson TJ(C), Levy AP (PI). Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. J Am Coll Cardiol. 2016; 67: 2553-5. Impact factor: 18.6; 3/136 (Cardiac and Cardiovascular Systems); 2.
20. Alshiek JA (PI), Dayan L (C), **Asleh R** (C), Blum S (C), Levy AP (C), Jacob G (PI). Anti-Oxidative Treatment With Vitamin E Improves Peripheral Vascular Function in Patients With Diabetes Mellitus and Haptoglobin 2-2 Genotype: A Double-Blinded Cross-Over Study. Diabetes Res Clin Pract. 2017;131:200-207. Impact factor: 3.2; 69/145 (Endocrinology and Metabolism); 6.
21. Akintoye E (PI), Briasoulis A (C), Egbe A (C), Adegbala O (C), Sheikh M (C), Singh M (C), Alliu S (C), Ahmed A (C), **Asleh R** (C), Kushwaha S (C), Levine D (PI). Regional Variation in Mortality, Length of Stay, Cost, and Discharge Disposition Among Patients Admitted for Heart Failure in the United States. Am J Cardiol. 2017;120(5):817-824. Impact factor: 2.8; 59/136 (Cardiac and Cardiovascular Systems); 3.
22. **Asleh R** (PI), Briasoulis A (C), Schettle SD (C), Tchantchaleishvili V (C), Pereira NL (C), Edwards BS (C), Clavell AL (C), Maltais S (C), Joyce DL (C), Joyce LD (C), Daly RC (C), Kushwaha SS (C), Stulak JM (PI). Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices: A Single Institutional 9-Year Experience. Circulation Heart Fail. 2017 Nov;10(11). pii: e004213. doi:10.1161/CIRCHEARTFAILURE. 117.004213. Impact factor: 6.5; 14/136 (Cardiac and Cardiovascular Systems); 7.

23. Briasoulis A (PI), Inampudi C (C), Pala M (C), **Asleh R** (C), Alvarez P (C), Bhama J (PI). Induction Immunosuppressive Therapy in Cardiac Transplantation: A Systematic Review and Meta-Analysis. Heart Fail Rev. 2018;23:641-649. doi: 10.1007/s10741-018-9691-2. Impact factor: 4.0; 43/136 (Cardiac and Cardiovascular Systems); 6.
24. Briasoulis A (PI), Inampudi C (C), Akintoye E (C), Adegbala O (C), **Asleh R** (C), Alvarez P (C), Bhama J (PI). Regional Variation in Mortality, Major Complications, and Cost After Left Ventricular Assist Device Implantation in the United States (2009 to 2014). Am J Cardiol. 2018;121:1575-1580. Impact factor: 2.8; 59/136 (Cardiac and Cardiovascular Systems); 0.
25. **Asleh R** (PI), Briasoulis A (C), Berinstein E (C), Wiener J (C), Palla M (C), Kushwaha SS (C), Levy AP (PI). Meta-Analysis of the Association of the Haptoglobin Genotype With Cardiovascular Outcomes and the Pharmacogenomic Interactions With Vitamin E Supplementation. Pharmgenomics Pers Med. 2018. Apr 23;11:71-82. Impact factor: 2.7; 123/267 (Pharmacology and Pharmacy); 5.
26. **Asleh R** (PI), Prasad M (C), Briasoulis A (C), Nardi V (C), Adigun R (C), Edwards BS (C), Pereira NL (C), Daly RC (C), Lerman A (C), Kushwaha SS (PI). Uric Acid Is an Independent Predictor of Cardiac Allograft Vasculopathy After Heart Transplantation. J Heart Lung Transplant. 2018;37:1083-1092. doi: 10.1016/j.healun.2018.04.017. Impact factor: 8.6; 1/25 (Transplantation), 3/203 (Surgery); 0.
27. **Asleh R** (PI), Hasin T (C), Briasoulis A (C), Schettle SD (C), Borlaug BA (C), Behfar A (C), Pereira NL (C), Edwards BS (C), Clavell AL (C), Joyce LD (C), Maltais S (C), Stulak JM (C), Kushwaha SS (PI). Hemodynamic Assessment of Patients Supported by a Continuous Flow Left Ventricular Assist Device With and Without Heart Failure Symptoms. Mayo Clin Proc. 2018; 93:895-903. Impact factor: 7.1; 12/160 (Medicine, General, and Internal); 2.
28. **Asleh R** (PI), Briasoulis A (C), Kremers WK (C), Adigun R (C), Boilson BA (C), Pereira NL (C), Edwards BS (C), Clavell AL (C), Schirger JA (C), Rodeheffer RJ (C), Frantz RP (C), Joyce LD (C), Maltais S (C), Stulak JM (C), Daly RC (C), Tilford J (C), Choi WG (C), Lerman A (C), Kushwaha SS (PI). Long-Term Use of Sirolimus as Primary Immunosuppression Attenuates Cardiac Allograft Vasculopathy Progression and Improves Clinical Outcomes in Heart Transplant Recipients. J Am Coll Cardiol. 2018. 13;71(6):636-650. Impact factor: 18.6; 3/136 (Cardiac and Cardiovascular Systems); 14.
29. **Asleh R** (PI), Briasoulis A (C), Pereira NL (C), Boilson BA (C), Edwards BS (C), Adigun R (C), Maltais S (C), Daly RC(C), Lerman A (C), Kushwaha SS (PI). Timing of HMG-CoA Reductase Inhibitor Initiation and Allograft Vasculopathy Progression and Outcomes in Heart Transplant Recipients. ESC Heart Failure. 2018;5:1118-1129. Impact factor: 3.4; 49/136 (Cardiac and Cardiovascular Systems); 0.

30. **Asleh R** (PI), Snipelisky D (C), Hathcock M (C), Kremers W (C), Liu D (C), Batzler A (C), Jenkins G (C), Kushwaha S (C), Pereira NL (PI). Genomewide Association Study Reveals Novel Genetic Loci Associated With Change in Renal Function in Heart Transplant Recipients. Clin Transplant. 2018 Oct;32: 13395.doi:10.1111/ctr.13395. Impact factor: 1.7; 17/25 (Transplantation), 113/203 (Surgery); 0.

31. **Asleh R** (PI), Briasoulis A (C), Pereira NL (C), Edwards BS (C), Frantz RP (C), Daly RC (C), Lerman A (C), Kushwaha SS (PI). Hypercholesterolemia After Conversion to Sirolimus as Primary Immunosuppression and Cardiac Allograft Vasculopathy in Heart Transplant Recipients. J Heart Lung Transplant. 2018;37:1372-1380. Impact factor: 8.6; 1/25 (Transplantation), 3/203 (Surgery); 1.

32. Dahan I (PI), Thawho N (C), Farber E (C), Nakhoul N (C), **Asleh R** (C), Levy AP (C), Li YC (C), Ben-Izhak O (C), Nakhoul F (PI). The Iron-Klotho-VDR Axis Is a Major Determinant of Proximal Convoluted Tubule Injury in Haptoglobin 2-2 Genotype Diabetic Nephropathy Patients and Mice. J Diabetes Res. 2018;2018: 7163652. doi: 10.1155/2018/7163652. Impact factor: 3.0; 75/145 (Endocrinology and Metabolism), 62/136 (Medicine, Research, and Experimental); 0.

33. **Asleh R** (PI), Levy AP (C), Levy NS (C), Asleh A (C), Goldenstein H (C), Segol I (C), Gulati R (C), Lerman LO (C), Lerman A (PI). Haptoglobin Phenotype Is Associated with HDL-Bound Hemoglobin Content and Coronary Endothelial Dysfunction in Patients With Nonobstructive Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2019 Apr;39:774-786. Impact factor: 6.6; 4/65 (Peripheral Vascular Disease), 8/73 (Hematology); 0.

34. Briasoulis A (PI), Akintoye E (C), Mohsen A (C), Inampudi C (C), Briasouli A (C), **Asleh R** (C), Alvarez P (C). Trends in Utilization, Mortality, Major Complications, and Cost After Total Artificial Heart Implantation in the United States (2009-2015). Hellenic J Cardiol. 2019. pii: S1109-9666(18)30522-0. doi: 10.1016/j.hjc.2019.02.002. Impact factor: 2.3; 73/136 (Cardiac and Cardiovascular Systems); 1.

35. Inampudi C (PI), Akintoye E (C), Bengaluru Jayanna M (C), **Asleh R** (C), Alvarez P (C), Briasoulis A (PI). Trends in In-Hospital Mortality, Length of Stay, Nonroutine Discharge, and Cost Among End-Stage Renal Disease Patients on Dialysis Hospitalized With Heart Failure (2001-2014). J Card Fail. 2019;25:524-533. doi:0.1016/j.cardfail.2019.02.020. Impact factor: 4.0; 44/136 (Cardiac and Cardiovascular Systems); 0.

36. **Asleh R** (PI), Enriquez-Sarano M (C), Jaffe AS (C), Manemann SM (C), Weston SA (C), Jiang R(C), Roger VL (PI). Galectin-3 Levels and Outcomes After Myocardial Infarction: A Community Study. J Am Coll Cardiol. 2019;73:2286-2295.doi: 10.1016/j.jacc.2019.02.046. Impact factor: 18.6; 3/136 (Cardiac and Cardiovascular Systems); 1.

37. Briasoulis A (PI), Inampudi C (C), Hatzis G (C), **Asleh R** (PI). Management of Patients With Heart Failure: Focus on New Pharmaceutical and Device Options. Curr Med Chem. 2019. doi: 10.2174/0929867326666190523083747. Impact factor: 3.9; 55/267 (Pharmacology and Pharmacy), 12/61 (Chemistry, Medical); 0.

38. **Asleh R** (PI), Clavell AL (C), Pereira NL (C), Smith B (C), Briasoulis A (C), Alnsasra H (C), Kremers WK (C), Habermann TM (C), Otley CC (C), Li X (C), Edwards BS (C), Stulak JM (C), Daly RC (C), Kushwaha SS (PI). Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. J Am Coll Cardiol. 2019;73:2676-2688. doi: 10.1016/j.jacc.2019.03.499. Impact factor: 18.6; 3/136 (Cardiac and Cardiovascular Systems); 1.

39. **Asleh R** (PI), Schettle S (C), Briasoulis A (C), Killian JM (C), Stulak JM (C), Pereira NL (C), Kushwaha SS (C), Maltais S (C), Dunlay SM (PI). Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation. Mayo Clin Proc. 2019;94:1003-1014. doi: 10.1016/j.mayocp.2018.09.021. Impact factor: 7.1; 12/160 (Medicine, General, and Internal); 0.

40. Alnsasra H (PI), **Asleh R** (C), Schettle SD (C), Pereira NL (C), Frantz RP (C), Edwards BS (C), Clavell AL (C), Maltais S (C), Daly RC (C), Stulak JM (C), Rosenbaum AN (C), Behfar A (C), Kushwaha SS (PI). Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. J Am Heart Assoc. 2019;8:e012073. doi: 10.1161/JAHA.119.012073. Impact factor: 4.7; 34/136 (Cardiac and Cardiovascular Systems); 0.

41. Santos CD (PI), Matos NL (C), **Asleh R** (C), Dawit S (C), Rabinstein AA (C), O'Carroll CB (C), Li Z (C), Freeman WD (PI). The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices. Neurocrit Care. 2019. doi: 10.1007/s12028-019-00836-y. Impact factor: 2.9; 12/33 (Critical Care Medicine), 83/199 (Clinical Neurology); 0.

42. **Asleh R** (PI), Schettle SS (C), Khan FW (C), Kushwaha SS (C). Left Ventricular Assist Devices as Destination Therapy in Stage D Heart Failure. J Geriatr Cardiol. 2019;16:592-600. doi: 10. 11909/j.issn.1671-5411.2019.08.009. Impact factor: 1.8; 95/136 (Cardiac and Cardiovascular Systems); 0.

43. **Asleh R** (PI), Alnsasra H (C), Daly RC (C), Schettle SD (C), Briasoulis A (C), Taher R (C), Dunlay SM (C), Stulak JM (C), Behfar A (C), Pereira NL (C), Frantz RP (C), Edwards BS (C), Clavell AL (C), Kushwaha SS (PI). Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist

Devices. J Am Heart Assoc. 2019. 9;8(22):e013108. doi: 10.1161/JAHA.119.013108. Impact factor: 4.7; 34/136 (Cardiac and Cardiovascular Systems); 0.

44. Briasoulis A (PI), Gao Y (C), Inampudi C (C), Alvarez P (C), **Asleh R** (C), Chrischilles E (C), Leira E (C), Vaughan-Sarrazin M (C). Characteristics and Outcomes in Patients With Atrial Fibrillation Receiving Direct Oral Anticoagulants in Off-Label Doses. BMC Cardiovascular Disorders. 2020 Feb 3;20(1):42. doi: 10.1186/s12872-020-01340-4. Impact factor: 2.0; 86/136 (Cardiac and Cardiovascular Systems); 0.

45. Gerber Y (PI), Gibbons RJ (C), Weston SA (C), Fabbri M (C), Herrmann J (C), Manemann SM (C), Frye RL (C), **Asleh R** (C), Greason K (C), Killian JM (C), Roger VL (PI). Coronary Disease Surveillance in the Community: Angiography and Revascularization. J Am Heart Assoc. 2020 Apr 7;9(7):e015231. doi: 10.1161/JAHA.119.015231. Impact factor: 4.7; 34/136 (Cardiac and Cardiovascular Systems); 0.

46. Kuno T (PI), Ueyama H (C), **Asleh R** (C), Briasoulis A (C). Maintenance immunosuppression in Heart Transplantation: Insights From Network Meta-Analysis of Various immunosuppression Regimens. Heart Fail Rev. 2020 May 18. doi: 10.1007/s10741-020-09967-3. Impact factor: 4.0; 43/136 (Cardiac and Cardiovascular Systems); 0.

47. **Asleh R** (PI), Albitar HA (C), Schettle SD (C), Kushwaha SS (C), Pereira NL (C), Behfar A (C), Stulak JM (C), Rodeheffer JR (C), Iyer VN (PI). Intravenous Bevacizumab as a Novel Treatment for Refractory Left Ventricular Assist Device-Related Gastrointestinal Bleeding. J Heart Lung Transplant. 2020 May;39(5):492-495. doi: 10.1016/j.healun.2020.02.012. Impact factor: 8.6; 1/25 (Transplantation), 3/203 (Surgery); 0.

48. **Asleh R** (PI), Manemann SM (C), Weston SA (C), Bielinski SJ (C), Chamberlain AM (C), Jiang R (C), Gerber Y (C), Roger VL (PI). Sex Differences in Outcomes After Myocardial Infarction in the Community. Am J Med. 2020. Accepted. Impact factor: 5.4; 17/160 (Medicine, General, and Internal); 0.

49. **Asleh R** (PI), Alnsasra H (C), Lerman A (C), Briasoulis A (C), Pereira NL (C), Edwards B (C), Toya T (C), Stulak JM (C), Clavell AL (C), Daly RC (C), Kushwaha SS (PI). Effects of mTOR Inhibitor-Related Proteinuria on Progression of Cardiac Allograft Vasculopathy and Outcomes among Heart Transplant Recipients. Am J Transplant. 2020 Jun 18. doi: 10.1111/ajt.16155. Online ahead of print. Impact factor: 7.2; 2/25 (Transplantation), 4/203 (Surgery); 0.

50. **Asleh R** (PI), Alnsasra H (PI), Oh J, Maleszewski J (C), Lerman A (C), Toya T (C), Chandrasekaran K (C), Bois M (C), Kushwaha SS (PI). The Impact of Sirolimus as a Primary Immunosuppressant on Myocardial Fibrosis and Diastolic Function Following Heart

Transplantation. J Am Heart Assoc. 2021. Accepted. Impact factor: 4.7; 34/136 (Cardiac and Cardiovascular Systems); 0.

51. Briasoulis A (PI), Ueyama H (C), Kuno T (C), **Asleh R** (C), Alvarez P (C), Malik AH (C). Trends and outcomes of device-related 30-day readmissions after left ventricular assist device implantation. Eur J Intern Med. 2021;84:56-62. Impact factor: 4.3; 26/165 (Medicine, General, and Internal); 0.

52. Nachman D (PI), **Asleh R** (C), Amir O (C). Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches? Curr Opin Cardiol. 2021 Mar 1;36(2):211-218. . Impact factor: 2.2; 80/138 (Cardiac and Cardiovascular Systems); 0.

53. Akintoye E (PI), **Asleh R** (C), Alvarez P (C), Briasoulis A (PI). Longitudinal trends and outcomes of adult heart transplantation in the U.S. Eur J Intern Med. 2021 Jan 22:S0953-6205(21)00001-7. doi: 10.1016/j.ejim.2021.01.001. Online ahead of print. Impact factor: 4.3; 26/165 (Medicine, General, and Internal); 0.

54. **Asleh R** (PI), Briasoulis A (C), Smith B (C), Lopez C (C), Alnsasra H (C), Pereira NL (C), Edwards BS (C), Clavell AL (C), Stulak JM (C), Locker C (C), Kremers WK (C), Daly RC (C), Lerman A (C), Kushwaha SS (PI). Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation. J Card Fail. 2021. Accepted. Impact factor: 3.6; 50/138 (Cardiac and Cardiovascular Systems); 0.

CASE REPORTS

MULTICENTER STUDIES

LETTERS

1. **Asleh R** (PI), Levy AP (C), Blum S (C). Cholesterol Efflux Capacity and Atherosclerosis. N Engl J Med. 2011; 14;364 (15):1473. Impact factor: 70.7; 1/154 (Medicine, General, and Internal); 5.
2. Schettle S (PI), Al Bawardy B (C), **Asleh R** (C), Sherazi S (C), Stulak JM (C), Pereira NL (PI). Danazol Treatment of Gastrointestinal Bleeding in Left Ventricular Assist Device-

Supported Patients. J Heart Lung Transplant. 2018;37:1035-1037. doi: 10.1016/j.healun. 2018.04.013. Impact factor: 8.6; 1/25 (Transplantation), 3/203 (Surgery); 2.

3. **Asleh R** (PI), Kremers WK (C), Kushwaha SS (PI). Reply: Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage? J Am Coll Cardiol. 2018;71:2860-2861. doi: 10.1016/j.jacc.2018.03.529. Impact factor: 18.6; 3/136 (Cardiac and Cardiovascular Systems); 0.

REVIEWS, COMMENTARIES, HYPOTHESES, EDITORIALS

1. **Asleh R** (PI), Levy AP (PI). In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease. Vasc Health Risk Manag. 2005; 1: 19-28. Impact factor: 3.3; Q1 (Cardiology and Cardiovascular Medicine); 75.
2. Nakhoul FM (PI), Miller-Lotan R (C), Awaad H (C)**, Asleh R** (C), Levy AP (PI). Hypothesis: Haptoglobin Genotype and Diabetic Nephropathy. Nature Clin Pract Neph. 2007; 3:339-344. Impact factor: 19.7; 1/80 (Urology and Nephrology); 32.
3. Levy AP (PI), **Asleh R** (PI), Blum S (PI), Levy NS (C), Miller-Lotan R (C), Kalet-Litman S (C), Anbinder Y (C), Lache O (C), Nakhoul FM (C), Asaf R (C), Farbstein D (C), Pollak M (C), Solveitchik YZ (C), Strauss M (C), Alshiek J (S), Livshits A (C). Schwartz A (C), Awad H (C), Jad K (S), Goldstein H (C). Haptoglobin: Basic and Clinical Aspects. Antioxidant Redox Signaling. 2010; 12:293-304. Impact factor: 5.8; 41/299 (Biochemistry and Molecular Biology), 19/145 (Endocrinology and Metabolism); 190.
4. Nakhoul FM (PI), Nakhoul N (C), **Asleh R** (C), Miller-Lotan Rachel (C), Levy AP (C). Is the Hp 2-2 Diabetic Mouse Model a Good Model to Study Diabetic Nephropathy? Diabetes Res Clin Pract. 2013; 100 (3): 289-297. Impact factor: 3.2; 69/145 (Endocrinology and Metabolism); 4.
5. Nakhoul FM (PI), Inbal D (C), Nakhoul N (C), Evgeny F (C), Miller-Lotan R (C), Levy AP (C), **Asleh R** (PI)**.** Vitamin E and Diabetic Nephropathy in Mice Model and Humans. World Journal of Nephrology. 2013; 6:111-24. Impact factor: not available now, x (Urology and Nephrology), 5.
6. **Asleh R** (PI), Sheikh-Ahmad M (C), Briasoulis A (C), Kushwaha SS (C). The Influence of Anti-Hyperglycemic Drug Therapy on Cardiovascular and Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus. Heart Fail Rev. 2018;23:445-459. doi: 10.1007/s10741-017-9666-8. Impact factor: 4.0; 43/136 (Cardiac and Cardiovascular Systems); 3.
7. Inampudi C (PI), Alvarez P (C), **Asleh R** (C), Briasoulis A (PI). Therapeutic Approach to Patients With Heart Failure With Reduced Ejection Fraction and End-stage Renal Disease. Curr Cardiol Rev. 2018;14:60-66. Impact factor: 1.8; Q2 (Medicine); 3.

8. Briasoulis A (PI), **Asleh R** (PI). Cardiovascular Risk Prediction in Older Adults With the Use of Biomarkers. Ann Transl Med. 2018 Nov;6(Suppl 1):S50. doi: 10.21037/atm.2018.10.10. Impact factor: 3.7; 47/136 (Medicine, Research, and Experimental); 2.
9. **Asleh R** (PI), Resar JR (PI). Utilization of Percutaneous Mechanical Circulatory Support Devices in Cardiogenic Shock Complicating Acute Myocardial Infarction and High-Risk Percutaneous Coronary Interventions. J Clin Med. 2019;8. pii: E1209. doi: 10.3390/jcm8081209. Impact factor: 5.7; 15/160 (Medicine, General, and Internal); 0.
10. **Asleh R** (PI), Amir O (C), Kushwaha SS (C). Editorial: Dynamics of Myocardial Fibrosis After Left Ventricular Assist Device Implantation: Should Speeding Up the Scar Have Us Scared Stiff? Eur J Heart Fail. 2020 Dec. Accepted. Doi:10.1002/ejhf.2085. Online ahead of print. Impact factor: 11.6; 9/138 (Cardiac and Cardiovascular Systems); 0.

OTHER PUBLICATIONS (Instruction manuals, Teaching aids etc.)

CDROMS, AUDIOTAPES, VIDEOTAPES

Asleh R. Heart Failure and Continuous-Flow Left Ventricular Assist Devices [podcast]. Mayo Clinic Proceedings. June, 2018. 1 poscast: 10 min.

https://www.dropbox.com/s/dtyasie1nm5khb8/9307_JMCP1965_Aslevideofina l.mp4?dl=0

PATENTS

CONFERENCES

INTERNATIONAL (ORAL OR POSTER PRESENTATIONS)

1. 2003 - AHA Scientific Sessions. Orlando, Florida, USA. Haptoglobin Genotype and Clearance of Hemoglobin (Moderated Poster Presentation).
2. 2005 - AHA Scientific Sessions. Dallas, Texas, USA. Haptoglobin Genotype and Iron Mediated Oxidative Stress (Poster Presentation).
3. 2006 - AHA Scientific Sessions. Chicago, Illinois, USA. Labile Plasma Iron Predicts Mortality After Myocardial Infarction in Patients With Diabetes (Poster Presentation).
4. 2007 - AHA Scientific Sessions. Orlando, Florida, USA. Special Session on Diabetes.

Council on Nutrition, Physical Activity and Metabolism (NPAM). Regulation of HDL Function by Haptoglobin (AHA Young Investigator Award) (Oral Presentation, Keynote Speaker).

5. 2008 - ACC Scientific sessions. Chicago, Illinois,USA. HDL Dysfunction in Diabetes and the Haptoglobin 2-2 Genotype (Moderated Poster Presentation).
6. 2008 - AHA Scientific Sessions. New Orleans, Louisiana, USA. Council on Basic Cardiovascular Sciences (BCVS). Correction of HDL Dysfunction in Haptoglobin 2-2 Individuals With Diabetes Mellitus. (Marcus Young Investigator Award) (Oral Presentation, Keynote Speaker).
7. 2009 - AHA Scientific Sessions. Orlando, Florida, USA. Targeting HDL Quality Rather Than Quantity: HDL Dysfunction in Haptoglobin 2-2 Diabetic Patients (Moderated Poster).
8. 2011 - The 10th Indo-Italian Workshop on Chemistry and Biology of Antioxidants. Rome, Italy. Pharmacogenomic Approaches to Improve HDL Function and Reduce Diabetic Cardiovascular Disease (Oral Presentation, Invited Lecture).
9. 2012 - Santa Foulkes Prize Lecture. Cambridge University, UK. Haptoglobin Genotype and Diabetic Vascular Diseases. (Santa Foulkes Award- Foulkes Foundation, UK) (Oral presentation, Keynote Speaker).
10. 2013 - American Diabetes Association (ADA) Scientific Sessions. Chicago, Illinois, USA. Accelerated Atherosclerosis in Individuals With the Haptoglobin 2-2 Genotype and Diabetes Is Mediated by Macrophage Lysosomal Injury and Apoptosis (Poster Presentation).
11. 2014 - AHA Scientific Sessions. Chicago, Illinois, USA. HDL-Induced Cholesterol Efflux Capacity From Niacin Therapy in Diabetes Is Haptoglobin Genotype-Dependent (Moderated Poster Presentation).
12. 2017 - ACC Scientific sessions. Washington DC, USA. Sirolimus-Based Immunosuppression for Attenuation of Cardiac Allograft Vasculopathy (CAV) and CAV-Related Events After Heart Transplantation (Moderated Poster Presentation).
13. 2017 - ACC Scientific sessions. Washington DC, USA. Impact of Diabetes Mellitus on Outcomes and Changes in Glycemic Control After Left Ventricular Assist Device (LVAD) Implantation (Poster Presentation).
14. 2017 - ISHLT Meeting. San Diego, Ca, USA. Sirolimus-Based Immunosuppression for Attenuation of Cardiac Allograft Vasculopathy (CAV) and CAV-Related Events After Heart Transplantation (Oral Presentation, Invited Lecture).
15. 2017 - ISHLT Meeting. San Diego, Ca, USA. Impact of Diabetes Mellitus on Outcomes and Changes in Glycemic Control After Left Ventricular Assist Device (LVAD) Implantation (Oral Presentation, Invited Lecture).

16. 2017 - AHA Scientific Sessions. Anaheim, Ca, USA. Persisting Sex-Specific Differences in Outcomes After Myocardial Infarction: A Population-Based Cohort Study (Poster Presentation).
17. 2017 - AHA Scientific Sessions. Anaheim, Ca, USA. Uric Acid Is an Independent Predictor of Cardiac Allograft Vasculopathy After Heart Transplantation (Poster presentation).
18. 2017 - AHA Scientific Sessions. Anaheim, Ca, USA. Timing of HMG-CoA Reductase Inhibitors on Allograft Vascolopathy Progression and Outcomes in Heart Transplant Recipients (Poster Presentation).
19. 2018 - ACC Scientific sessions. Orlando Fl, USA. The Impact of Circulating Galectin-3 Levels on Long-Term Outcomes After Myocardial Infarction in the Community (Moderated Poster Presentation).
20. 2018 - ACC Scientific sessions. Orlando Fl, USA. Differential Effects of Sirolimus- and Calcineurin Inhibitor-Associated Hyperlipidemia on Cardiac Allograft Vasculopathy Progression and Outcomes After Heart Transplantation (Moderated Poster Presentation).
21. 2018 - ASAIO conference. Washington DC, USA. Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation (Poster Presentation).
22. 2018 - AHA Scientific Sessions. Chicago, IL, USA. Long-Term Sirolimus for Primary Immunosuppression and Incidence of De Novo Malignancy Following Heart Transplantation (Oral Presentation, Invited Lecture).
23. 2018 - AHA Scientific Sessions. Chicago, IL, USA. Genome Wide Association Study Reveals Novel Genetic Loci Associated With Change in Renal Function in Heart Transplant Recipients (Oral Presentation, Invited Lecture).
24. 2019 - ACC Scientific sessions. New Orleans, Louisiana, USA. Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices (Poster Presentation).
25. 2019 - ISHLT Meeting. Orlando, Orlando FL, USA. Promising Novel Treatment With Intravenous Bevacizumab for Refractory Gastrointestinal Bleeding From Angiodysplastic Lesions in Patients Supported with a Continuous-Flow Left Ventricular Assist Device: A Pilot Study (Oral Presentation, Invited Lecture).
26. 2019 - ISHLT Meeting. Orlando, Orlando FL, USA. Sirolimus Therapy and Incidence of De Novo Malignancy Following Heart Transplantation (Poster Presentation).
27. 2019 - ISHLT Meeting. Orlando, Orlando FL, USA. Length of Continuous-Left Ventricular Assist Device Support and Short-Term Outcomes After Heart transplantation (Oral Presentation, Invited Lecture).

NATIONAL (ORAL OR POSTER PRESENTATIONS)

28. 2003 - The Annual International Diabetes Conference, Tel-Aviv, Israel. Haptoglobin Genotype and Diabetic Vascular Diseases (Oral Presentation, Invited Lecture).
29. 2003 - The Annual Graduate Students Meeting in the Technion. Haifa, Israel. Haptoglobin Genotype and Diabetic Vascular Diseases (Oral Presentation, Invited Lecture).
30. 2004 - The Annual Graduate Students Meeting in the Technion. Haifa, Israel. Haptoglobin Genotype and Clearance of Hemoglobin During Intra-Plaque Hemolysis (Poster Presentation).
31. 2004 - The Israeli Conference for Prevention and Treatment of Atherosclerosis. Haifa, Israel. Genetic Susceptibility for Atherosclerosis Progression in Diabetes (Oral Presentation, Invited Lecture).
32. 2004 - The Annual International Diabetes Conference, Tel-Aviv, Israel. Haptoglobin Genotype and Iron-Mediated Oxidative Stress (Oral Presentation, Invited Lecture).
33. 2005 - The Israel Heart Society Conference. Haifa, Israel. Haptoglobin Polymorphism as an Independent Predictor of Diabetic Cardiovascular disease (Oral Presentation, Invited Lecture).
34. 2005 - The Annual International Diabetes Conference, Tel-Aviv, Israel. Haptoglobin Genotype Modulates Hemoglobin-Driven Oxidative Stress in Diabetes (Oral Presentation, Invited Lecture).
35. 2005 - Russell Berrie International Symposium in Diabetes and Atherosclerosis. Jerusalem, Israel. Labile Plasma Iron Predicts Mortality After MI in Patients With Diabetes Mellitus. (Israeli Young Investigator Award, D-Cure) (Oral Presentation, Invited Lecture).
36. 2006 - Russell Berrie International Symposium in Diabetes and Atherosclerosis. Jerusalem, Israel. Regulation of HDL Function by Haptoglobin (Oral Presentation, Invited Lecture).
37. 2008 - The Israel Heart Society Conference. Tel-Aviv, Israel. Genetic Predisposition of HDL Dysfunction Based on the Haptoglobin Polymorphism (Oral Presentation, Invited Lecture).
38. 2009 - The Israel Heart Society Conference. Tel-Aviv, Israel. HDL Dysfunction in Hp 2-2 Diabetic Patients. (Henry Neufeld Cardiovascular Research Award) (Oral Presentation, Keynote Speaker).
39. 2009 - The 25th Annual meeting of the Israeli Society for Oxygen and Free Radicals Research. Tel-Aviv, Israel. Haptoglobin Genotype and Iron-Mediated Oxidative Modifications of Lipoproteins (Oral Presentation, Invited Lecture).

40. 2010 - Semi-annual meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis. Tel-Aviv, Israel. Targeting HDL Quality Rather Than Quantity: HDL Dysfunction in Haptoglobin 2-2 Diabetic Individuals (Oral Presentation, Invited Lecture).
41. 2010 - Israeli Society for Research, Prevention and Treatment of Atherosclerosis. Eilat, Israel. Pharmacogenomic Application of HDL in the Prevention of Diabetic Cardiovascular Disease. (Young Investigator Grant) (Oral Presentation, Invited Lecture)
42. 2011- Annual Rambam Research Seminar. Rambam Health Care Center. Haifa, Isreal. Haptoglobin Is a Regulator of oxidative Lysosomal Injury and Apoptosis in Diabetes (Oral Presentation, Invited Lecture).
43. 2012 - Annual Rambam Cardiology and Cardiac Surgery Conference. Haptoglobin Genotype Modulates Lysosomal Loss of Integrity and Apoptosis in Diabetes mellitus. Rambam Medical Center, Haifa, Israel (Recipient of Lusatso Award) (Oral Presentation, Keynote Speaker).
44. 2012 - Semi-Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis. Hadassah University Medical Center, Jerusalem, Israel. HDL Dysfunction and Apoptosis in Diabetes Mellitus Are Mediated by the Haptoglobin Genotype (Poster Presentation).
45. 2012 - Lord`s Turnberg Lecture, Foulkes Foundation. Rappaport Faculty of Medicine. Technion, Haifa, Isreal. Haptoglobin genotype and diabetic vascular diseases (Santa Foulkes Award) (Oral Presentation, Keynote Speaker).
46. 2012 - The Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis. Eilat, Israel. Accelerated Atherosclerosis in Individuals With the Haptoglobin 2-2 Genotype Is Mediated by Increased Macrophage Inflammation and Oxidative Injury in the Setting of Diabetes (Oral Presentation, Invited Lecture).
47. 2012 - Annual Rambam Research Seminar. Atidim Program Lecture. Haptoglobin Genotype Is a Key Regulator of Lysosomal Oxidative Injury and Apoptosis. Rambam Medical Center, Haifa, Isreal (Oral Presentation, Invited Lecture).
48. 2013 - Guest Lecture. The Baruch Padeh Medical Center, Poriya. Haptoglobin Genotype in Diabetic Cardiovascular Disease: A platform for Pharmacogenomic Applications (Oral Presentation, Invited Lecture).
49. 2014 - The Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis. Eilat, Israel. HDL-Induced Cholesterol Efflux Capacity From Niacin Therapy Is Haptoglobin Genotype-Dependent (Oral Presentation, Invited Lecture).
50. 2015 - The Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis. Haifa, Israel. HDL Oxidative Modification in Diabetes and the Haptoglobin 2-2 Genotype (Poster Presentation).
51. 2016 - The Israel Heart Society Conference. Tel-Aviv, Israel. Haptoglobin Genotype as a

Determinant of Benefit or Harm From Niacin for AIM-HIGH Participants With Diabetes (Oral Presentation, Invited Lecture).

52. 2019 - Hadassah Heart Failure and Electrophysiology Conference. Hadassah University Medical Center. Jerusalem, Israel. Advanced in Treatment of Heart Failure (Oral Presentation, Invited Lecture).
53. 2019 - Annual Meeting of Electrophysiology, Heart Failure, and Imaging WGs, Zichron Yaacov, Israel. Arrhythmia Management in Patients with Left Ventricular Assist Devices (Oral Presentation, Invited Lecture).
54. 2019 - ECMO Training Course, Hadassah University Medical Center. Timeline Management of the ECMO Patient (Oral Presentation, Invited Lecture).